Pharma-Bio Serv, Inc. (PBSV) Form 8-K — Sep 14, 2026
Pharma-Bio Serv announced results for its fiscal third quarter ended July 31, 2026, reporting revenue of approximately $2.3 million, up roughly $0.4 million versus the same period last year. Nine-month revenue reached approximately $7.3 million, an increase of about $0.5 million year over year. Profitability improved markedly on a small base: the company posted a Q3 net loss of just $14 thousand, a roughly $190 thousand improvement from the prior-year quarter, and swung to net income of approximately $252 thousand for the nine-month period, up about $352 thousand year over year.
Key figures
- Revenue
- approximately $2.3 million for the three months ended July 31, 2026; approximately $7.3 million for the nine months ended July 31, 2026
- Net Income
- net loss of $14 thousand for Q3; net income of approximately $252 thousand for the nine months ended July 31, 2026
- Revenue Yoy
- up approximately $0.4 million (Q3) and approximately $0.5 million (nine months) vs. prior-year periods
- Fiscal quarter end
- July 31, 2026
- Q3 revenue increase yoy
- approximately $0.4 million
- Q3 net income improvement yoy
- approximately $190 thousand
- Nine month revenue increase yoy
- approximately $0.5 million
- Nine month net income improvement yoy
- approximately $352 thousand
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.